PCI Biotech invites to a presentation of the company's fourth quarter and preliminary 2018 report NewsRonny SkuggedalFebruary 6, 2019
Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer NewsRonny SkuggedalDecember 20, 2018
Extension of preclinical research collaboration agreement with a top-10 large pharma company NewsRonny SkuggedalDecember 18, 2018
Last day of trading in subscription rights Monday 1 October 2018 NewsRonny SkuggedalSeptember 28, 2018
Mandatory notification regarding exercise and trade of subscription rights NewsRonny SkuggedalSeptember 20, 2018
Mandatory notification regarding exercise and trade of subscription rights NewsRonny SkuggedalSeptember 20, 2018
Key information relating to the preferential rights issue to be carried out by PCI Biotech Holding ASA NewsRonny SkuggedalAugust 24, 2018
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 360 million NewsRonny SkuggedalAugust 24, 2018
